. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » Androgen Antagonists/administration & dosageAndrogen Antagonists/adverse effectsAndrogen Antagonists/therapeutic useCastrationDose-Response Relationship, DrugDrug ApprovalDrug InteractionsGonadotropin-Releasing Hormone/antagonists & inhibitorsHumansMaleOligopeptides/administration & dosageOligopeptides/adverse effectsOligopeptides/therapeutic useProstatic Neoplasms/drug therapyProstatic Neoplasms/metabolismRandomized Controlled Trials as TopicReceptors, LHRH/metabolismTestosterone/antagonists & inhibitorsUnited StatesUnited States Food and Drug Administration
Substances： See more » Androgen AntagonistsOligopeptidesReceptors, LHRHacetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamideGonadotropin-Releasing HormoneTestosterone
Year: 2009 PMID： 19838145
Source DB: PubMed Journal: Med Lett Drugs Ther ISSN： 0025-732X Impact factor: 1.909